Patents by Inventor Todd Herrington

Todd Herrington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimera botulinum toxin type E
    Patent number: 8017741
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: September 13, 2011
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Nucleic acids encoding chimera botulinum toxin type E
    Patent number: 8008465
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: August 30, 2011
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • CLOSTRIDIAL NEUROTOXIN COMPOSITIONS AND MODIFIED CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100280222
    Abstract: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.
    Type: Application
    Filed: January 5, 2007
    Publication date: November 4, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd Herrington, Kei Roger Aoki
  • Chimera Botulinum Toxin Type E
    Publication number: 20100160609
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 8, 2010
    Publication date: June 24, 2010
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • CHIMERA BOTULINUM TOXIN TYPE E
    Publication number: 20100121042
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 8, 2010
    Publication date: May 13, 2010
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Chimera botulinum toxin type E
    Patent number: 7691983
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: April 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Chimera botulinum toxin type E
    Publication number: 20060039929
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 144) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 14, 2005
    Publication date: February 23, 2006
    Inventors: Ester Fernandez-Salas, Lance Steward, Todd Herrington, K. Aoki
  • Leucine-based motif and Clostridial neurotoxins
    Publication number: 20050276820
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
    Type: Application
    Filed: January 19, 2005
    Publication date: December 15, 2005
    Inventors: Lance Steward, Todd Herrington, Kei Aoki
  • Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins
    Publication number: 20050260230
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.
    Type: Application
    Filed: January 8, 2004
    Publication date: November 24, 2005
    Applicant: Allergan Sales, Inc.
    Inventors: Lance Steward, Ester Fernandez-Salas, Todd Herrington, Kei Aoki
  • Clostridial neurotoxin compositions and modified clostridial neurotoxins
    Publication number: 20030219462
    Abstract: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.
    Type: Application
    Filed: June 4, 2002
    Publication date: November 27, 2003
    Applicant: Allergan Sales, Inc
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd Herrington, Kei Roger Aoki